Latest & greatest articles for heart failure

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on heart failure or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on heart failure and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for heart failure

61. “Case management” can prevent people with heart failure being admitted again

“Case management” can prevent people with heart failure being admitted again “Case management” can prevent people with heart failure being admitted again Discover Portal Discover Portal “Case management” can prevent people with heart failure being admitted again Published on 30 August 2016 doi: Case management that is initiated in hospital and led by specialist nurses may reduce unplanned hospital readmissions and length of hospital stay for adults with heart failure. Case management (...) case management is cost effective – particularly in relation to the NHS. A few studies examined case management that was started in the community. The findings are promising and may lead to further studies that confirm these findings in the UK setting. Commissioners would also need to know other things too, such as the components of case management that are most beneficial and the costs. Share your views on the research. Why was this study needed? Heart failure is a condition where the heart

2019 NIHR Dissemination Centre

62. ‘Virtual wards’ reduce readmissions in people after hospitalisation for heart failure

‘Virtual wards’ reduce readmissions in people after hospitalisation for heart failure ‘Virtual wards’ reduce readmissions in people after hospitalisation for heart failure Discover Portal Discover Portal ‘Virtual wards’ reduce readmissions in people after hospitalisation for heart failure Published on 14 August 2018 doi: People with heart failure who receive care via virtual wards following discharge from hospital have lower rates of heart failure-related readmission and death than people (...) and more rounded approach to care may improve post-discharge outcomes in people with heart failure. The review described interventions that are applicable to UK care models. The evidence may be a starting point for further evaluation or trials of these. Share your views on the research. Why was this study needed? Unplanned readmissions of people within a short time after discharge from hospital are detrimental to both patients and healthcare systems. From 2009 to 2010, the cost to the NHS

2019 NIHR Dissemination Centre

63. Cost-Effectiveness of a Home Visit Program for Patients with Heart Failure in Brazil: Evidence from a Randomized Clinical Trial. (PubMed)

Cost-Effectiveness of a Home Visit Program for Patients with Heart Failure in Brazil: Evidence from a Randomized Clinical Trial. Estimate the cost-effectiveness of a nurse-led home visit (HV) intervention as compared with the standard HF management, within a randomized clinical trial in Brazil.Cost-effectiveness study within a randomized trial.To assess the cost-effectiveness of four home visits and four telephone calls by nurses in the management of patients with HF within a randomized

2019 Value in health regional issues

64. Disease management interventions for heart failure. (PubMed)

Disease management interventions for heart failure. Despite advances in treatment, the increasing and ageing population makes heart failure an important cause of morbidity and death worldwide. It is associated with high healthcare costs, partly driven by frequent hospital readmissions. Disease management interventions may help to manage people with heart failure in a more proactive, preventative way than drug therapy alone. This is the second update of a review published in 2005 and updated (...) in 2012.To compare the effects of different disease management interventions for heart failure (which are not purely educational in focus), with usual care, in terms of death, hospital readmissions, quality of life and cost-related outcomes.We searched CENTRAL, MEDLINE, Embase and CINAHL for this review update on 9 January 2018 and two clinical trials registries on 4 July 2018. We applied no language restrictions.We included randomised controlled trials (RCTs) with at least six months' follow-up

2019 Cochrane

65. Chronic congestive heart failure

Chronic congestive heart failure Chronic congestive heart failure - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Chronic congestive heart failure Last reviewed: February 2019 Last updated: January 2019 Summary A complex clinical syndrome that can result from any structural or functional cardiac disorder that impairs the ability of the ventricle to fill with or eject blood. It is a major and growing public health (...) problem. It is the only cardiovascular disease that is increasing in incidence and prevalence, partly because the population is ageing, but also because of improved cardiovascular interventions for disease processes that reduce early mortality but may result in cardiac changes that lead to heart failure. The key manifestations are dyspnoea and fatigue, which may limit exercise tolerance, and fluid retention, which may lead to pulmonary congestion and peripheral oedema. Diagnosis is largely clinical

2019 BMJ Best Practice

66. Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA

Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA Individuals with type 2 diabetes mellitus are at increased risk for heart failure (HF), particularly those with coexisting atherosclerotic cardiovascular disease and/or kidney disease. Some but not all dipeptidyl peptidase-4 inhibitors have been associated with increased HF risk. We performed secondary analyses of HF and related outcomes

2019 EvidenceUpdates

67. Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update

Meta-Analysis of Effects of Digoxin on Survival in Patients with Atrial Fibrillation or Heart Failure: An Update In 2015, 3 independent meta-analyses raised concerns about digoxin therapy being associated with an increased mortality risk in patients with atrial fibrillation (AF) and with heart failure (HF). Although several other studies have been published since then fostering these safety issues, the most recent 2016 European guidelines for AF still recommend this therapy as a class I

2019 EvidenceUpdates

68. Torsemide versus furosemide in chronic heart failure: a systematic review and meta-analysis

Torsemide versus furosemide in chronic heart failure: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

69. The efficacy of psychological interventions on health-related quality of life for heart failure patients with depression: a systematic review

The efficacy of psychological interventions on health-related quality of life for heart failure patients with depression: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

70. The effects of adding angiotensin receptor neprilysin inhibitors to usual care in patients with heart failure - a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis

The effects of adding angiotensin receptor neprilysin inhibitors to usual care in patients with heart failure - a protocol for a systematic review of randomised clinical trials with meta-analysis and trial sequential analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate

2019 PROSPERO

71. Uric acid and risk of heart failure mortality: a dose-response meta-analysis of prospective cohort studies

Uric acid and risk of heart failure mortality: a dose-response meta-analysis of prospective cohort studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

72. Telemonitoring and structured telephone support to monitor heart failure: systematic review and meta-analysis

Telemonitoring and structured telephone support to monitor heart failure: systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

73. The clinical efficacy and safety of Ginseng (Renshen) preparation as adjunctive therapy for the treatment of heart failure: a systematic review of randomized controlled trials

The clinical efficacy and safety of Ginseng (Renshen) preparation as adjunctive therapy for the treatment of heart failure: a systematic review of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

74. Sex differences in the association between diabetes and heart failure

Sex differences in the association between diabetes and heart failure Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

75. Efficacy and safety of 4 personal Chinese patent medicines in the treatment of chronic heart failure: a network meta-analysis

Efficacy and safety of 4 personal Chinese patent medicines in the treatment of chronic heart failure: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

76. Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): systematic review and meta-analysis of observational cohort studies conducted in large healthcare database

Cardiovascular outcomes, heart failure and mortality in type 2 diabetic patients treated with glucagon-like peptide 1 receptor agonists (GLP-1 RAs): systematic review and meta-analysis of observational cohort studies conducted in large healthcare database Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied

2019 PROSPERO

77. The effectiveness of transitional care programs in patients with heart failure: a systematic review

The effectiveness of transitional care programs in patients with heart failure: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

78. Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials

Role of cardioprotective agents on chemotherapy-induced heart failure: a systematic review and network meta-analysis of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

79. Systematic reviews of the quality and accuracy of prognostic models in heart failure

Systematic reviews of the quality and accuracy of prognostic models in heart failure Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO

80. Systematic reviews and meta-analyses of added-value biomarkers in heart failure prognosis

Systematic reviews and meta-analyses of added-value biomarkers in heart failure prognosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites

2019 PROSPERO